What this evidence supports
FDA announced two initiated real-time clinical-trial proofs of concept that report endpoints and data signals to FDA in real time. Separately, FDA requested information on a proposed AI-enabled early-phase clinical-trial pilot.
What it does not establish
The initiated reporting proofs do not establish comparative benefit or suitability for every trial. The separate AI-enabled pilot RFI closed June 29, 2026; the cited source does not establish a later selection or broader-pilot launch outcome.
Answer-ready summary
FDA initiated two real-time endpoint/data-signal reporting proofs of concept; a separate AI-enabled early-phase-trial pilot remained a proposal whose RFI closed June 29, 2026, and whose later selection or launch outcome is not established by the cited source.
Record details
- Decision priority
- Watch
- Current status
- Two proofs initiated · AI-enabled pilot RFI closed 2026-06-29 · broader pilot selection/launch outcome not established by cited source
- Evidence tracks
- Technologies/care models · Implementation/adoption
- Source authority
- Primary/authoritative
- Source organization
- FDA
- Evidence design
- Federal regulatory innovation initiative
- Applicability
- Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
- Confidence for the stated claim
- High
- Freshness
- Changed
- Record date
- 2026-04-28
- Source updated
- 2026-05-27
- Last verified
- 2026-09-03
- Review due
- 2026-10-03 or sooner if the cited source changes.
- Version
- 1.1
- Revision state
- Version 1.1 separates two initiated real-time reporting proofs from the distinct proposed AI-enabled pilot, records the RFI closure and unestablished later outcome, adds the RFI source, and records the September 3, 2026 re-verification.
Evidence record fields
- Claim supported
- FDA announced two initiated real-time clinical-trial proofs of concept that report endpoints and data signals to FDA in real time. Separately, FDA requested information on a proposed AI-enabled early-phase clinical-trial pilot.
- Source type and design
- Federal regulatory innovation initiative
- Population and setting
- Not a participant-level clinical-study population in this source type. The program, policy, regulatory, standards, or research context described by the cited source.
- Intervention/exposure and comparator
- Not evaluated as a comparative intervention or exposure in the cited administrative or program source. No comparator is reported for this source-bounded claim.
- Outcome or endpoint
- The program, policy, regulatory, standards, or development state stated in the claim supported; no clinical outcome is inferred.
- Follow-up duration
- No clinical follow-up duration is reported for this source-bounded claim.
- Effect estimate and uncertainty
- No clinical effect estimate is reported. No statistical uncertainty estimate is reported; uncertainty is bounded through the source scope and stated limitations.
- Harms/adverse events
- No harms or adverse-event analysis is reported for this source-bounded administrative or program claim.
- Missing data and attrition
- Not reported; this record does not analyze participant-level data. Not applicable or not reported; no longitudinal participant cohort is analyzed.
- Bias/limitations
- The initiated reporting proofs do not establish comparative benefit or suitability for every trial. The separate AI-enabled pilot RFI closed June 29, 2026; the cited source does not establish a later selection or broader-pilot launch outcome.
- Applicability/generalizability
- Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
- Funding/conflicts
- Funding or sponsorship is recorded only where the cited source and claim state it; otherwise it is not assessed in this record. No conflict-of-interest assessment is reported for this administrative or program-source record.
- Replication or corroboration
- The administrative or program claim is anchored to the cited authoritative source; independent clinical replication is not implied.
- Decision use
- Use as source-bounded context for Researchers, Innovators, Funders/investors, Policymakers, Clinicians; do not use as stand-alone evidence of safety, efficacy, coverage, endorsement, or scaled adoption.
- Last reviewed / review due
- Last reviewed 2026-09-03; review due 2026-10-03 or sooner if the cited source changes.
For this decision
Researchers · Innovators · Funders/investors · Policymakers · Clinicians